Académique Documents
Professionnel Documents
Culture Documents
Pr Patrice Morand
Laboratoire de Virologie
2016
Gertrude Elion
Prix Nobel de Médecine1988
aciclovir
Antiviraux : un peu d’histoire
Long-term retention in care and maintenance of successful antiretroviral therapy allow persons with HIV
infection to have a near-normal life span and virtually eliminate transmission of HIV to others
Saag MS New Engl J Med 2021
Antiviraux : les belles victoires
Antiviraux : les belles victoires … qui tardent
Antiviraux : l’histoire en marche
Paxlovid
(FDA approved)
fostemsavir
In patients with multidrug-resistant HIV-1 infection with limited therapy options, those who received fostemsavir
had a significantly greater decrease in the HIV-1 RNA level than those who received placebo during the first 8
days. Efficacy was sustained through 48 weeks.
EMU B, N Engl J Med 2018
Link J et al Nature 2020
GS-6207
Lenacapavir
. In phase-1 clinical studies, monotherapy with a single subcutaneous dose of GS-6207 (450 mg) resulted in a mean log10-transformed
reduction of plasma viral load of 2.2 after 9 days, and showed sustained plasma exposure at antivirally active concentrations
for more than 6 months
GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core
interaction with cellular factors
Selyutin A et al iScience 202121
Grippe (Influenza)
Grippe : de la structure atomique (synchrotron) à l’antiviral
Structure de la neuraminidase
(Colman PM. Nature 1983)
1993
Single-dose baloxavir has superior efficacy to placebo and similar efficacy to oseltamivir for
ameliorating influenza symptoms in high-risk outpatients
Comparison of Antiviral Agents for Seasonal Influenza Outcomes
in Healthy Adults and ChildrenA Systematic Review and Network Meta-analysis
Liu JW et al JAMA Network Open. 2021
“In vivo delivery of gene-editing tools to either target the virus, boost immunity
or protect cells from infection, also holds promise for future HIV cure strategies.”.
38
CRISPR/ cas9
( Clustered Regularly Interspeced Short Palindromic Repeats)
« Programmer une endonucléase bactérienne (Cas 9)
avec des petits ARNs non codants pour permettre le clivage a l’endroit désiré de l’ADN)»